Medicare Enrolled
Dr. Daniel Khera-McRackan, M.D.
Urology Physician · Raleigh, NC
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Khera-McRackan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Khera-McRackan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Khera-McRackan
Dr. Daniel Khera-McRackan is an urology physician in Raleigh, NC, with 19 years of NPI registration. Based on federal Medicare data, Dr. Khera-McRackan performed 10,007 Medicare services across 3,412 unique beneficiaries.
Between the years covered by Open Payments, Dr. Khera-McRackan received a total of $7,390 from 46 pharmaceutical and/or device companies across 407 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Khera-McRackan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 4% volume in NC
$7,390 industry payments
Medicare Practice Summary
Medicare Utilization ↗10,007
Medicare services
Top 4% in NC for urology physician
3,412
Unique beneficiaries
$22
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~527 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
4,550 | $0 | $10 |
| Creatinine test (kidney function) A blood test that measures the amount of creatinine to assess kidney function or detect muscle injury. |
987 | $5 | $19 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
892 | $84 | $208 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
589 | $2 | $8 |
| PSA test (prostate cancer screening) | 473 | $18 | $68 |
| Urinalysis with microscopic exam A urine test performed manually that includes examining the sample under a microscope to check for abnormalities. |
449 | $3 | $12 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
328 | $7 | $35 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 300 | $3 | $24 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 183 | $136 | $634 |
| Total testosterone level test A blood test that measures the total amount of testosterone in your body. This hormone is important for various bodily functions in both men and women. |
166 | $25 | $96 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
142 | $172 | $472 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
129 | $112 | $306 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
125 | $17 | $35 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
124 | $58 | $125 |
| Abdominal X-ray, 1 view An X-ray image of the abdomen taken from a single angle to visualize internal structures. |
94 | $13 | $51 |
| Bladder instillation of anti-cancer drug A procedure where an anti-cancer medication is introduced directly into the bladder. This method delivers the treatment locally to the bladder tissue. |
85 | $66 | $244 |
| Complete ultrasound of retroperitoneum An ultrasound examination of the structures located behind the abdominal cavity. |
76 | $48 | $217 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
67 | $24 | $88 |
| Blood creatinine level test A blood test that measures the amount of creatinine, a waste product from muscle wear and tear, to help assess kidney function. |
48 | $5 | $19 |
| Transrectal ultrasound of the pelvis An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures. |
45 | $105 | $279 |
| CT scan of abdomen and pelvis with contrast A CT scan of the abdomen and pelvis using contrast dye before and after administration to visualize internal structures. |
30 | $181 | $895 |
| Ureteral stent insertion via endoscope A flexible tube is inserted into the ureter using an endoscope to keep the passage open and allow urine to flow from the kidney to the bladder. |
27 | $102 | $830 |
| CT scan of abdomen and pelvis, without contrast A computed tomography scan that creates detailed images of the abdominal and pelvic organs. The procedure is performed without the use of intravenous contrast dye. |
22 | $77 | $250 |
| Prostate gland biopsy A procedure to remove small samples of tissue from the prostate gland for laboratory examination. |
18 | $174 | $723 |
| CT scan of abdomen with and without contrast A CT scan of the abdomen performed both before and after the administration of contrast dye to provide detailed images of internal structures. |
17 | $125 | $546 |
| Ureteral stone crushing with stent insertion An endoscope is used to break up a stone in the ureter, followed by the placement of a stent to keep the ureter open. |
16 | $326 | $1,230 |
| Laser vaporization of prostate A procedure that uses a laser to remove excess prostate tissue through an endoscope. The process includes controlling any bleeding that occurs during the treatment. |
13 | $532 | $5,336 |
| Endoscopic removal of bladder or urethra growth, 2.0-5.0 cm This procedure uses an endoscope to destroy or remove a growth from the bladder or urethra that measures between 2.0 and 5.0 centimeters. |
12 | $212 | $853 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.4% high complexity
54.5% medium
45.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,390
Total received (2018-2024)
Avg $1,056/year across 7 years
Top 23% in NC for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
407
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,279 (98.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$111 (1.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$842
2023
$1,369
2022
$1,441
2021
$1,338
2020
$604
2019
$956
2018
$840
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$218
Dendreon Pharmaceuticals LLC
$148
Sumitomo Pharma America, Inc.
$131
ABBVIE INC.
$91
Merck Sharp & Dohme LLC
$83
PFIZER INC.
$69
Myriad Genetic Laboratories, Inc.
$27
PROGENICS PHARMACEUTICALS, INC.
$27
UROGEN PHARMA, INC.
$19
Blue Earth Diagnostics Limited
$16
Antares Pharma, Inc.
$14
Top 3 companies account for 59.0% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$1,678
Janssen Biotech, Inc.
$1,004
Dendreon Pharmaceuticals LLC
$808
Merck Sharp & Dohme LLC
$412
Myriad Genetic Laboratories, Inc.
$359
Blue Earth Diagnostics Limited
$315
ABBVIE INC.
$306
Sumitomo Pharma America, Inc.
$276
UROVANT SCIENCES INC
$225
PFIZER INC.
$192
Antares Pharma, Inc.
$145
Allergan, Inc.
$128
Merck Sharp & Dohme Corporation
$118
Amgen Inc.
$90
AbbVie Inc.
$83
Bayer HealthCare Pharmaceuticals Inc.
$83
Acerus Pharmaceuticals Corporation
$81
Endo Pharmaceuticals Inc.
$80
PROCEPT BioRobotics Corporation
$77
Myovant Sciences Inc.
$75
Ferring Pharmaceuticals Inc.
$74
Olympus America Inc.
$66
TOLMAR Pharmaceuticals, Inc.
$62
Clarus Therapeutics Inc.
$61
Allergan Inc.
$60
UROGEN PHARMA, INC.
$47
AstraZeneca Pharmaceuticals LP
$41
AbbVie, Inc.
$38
BOSTON SCIENTIFIC CORPORATION
$37
UroGen Pharma, Inc.
$36
MEDIVATION FIELD SOLUTIONS LLC
$33
Janssen Scientific Affairs, LLC
$32
Tolmar, Inc.
$27
PROGENICS PHARMACEUTICALS, INC.
$27
Boston Scientific Corporation
$24
Avadel Specialty Pharmaceuticals, LLC
$22
Accord Healthcare, Inc.
$21
Baxter Healthcare
$20
Progenics Pharmaceuticals, Inc.
$18
Supernus Pharmaceuticals, Inc.
$18
Baudax Bio Inc.
$18
Travere Therapeutics, Inc.
$17
Telix Pharmaceuticals
$16
COLOPLAST CORP
$14
KARL STORZ Endoscopy-America
$13
Ambu Inc.
$11
Top 3 companies account for 47.2% of all-time payments
Associated products mentioned in payments ›
(815) Thiola · 16 FR. FLEXIBLE VIDEO CYSTOSCOPE · ABIRATERONE ACETATE · ANJESO · AQUABEAM ROBOTIC SYSTEM · Axumin · BOTOX · BOTOX THERAPEUTIC · BRAC CDx · BRACAnalysis CDx · CAMCEVI · ELIGARD · ERLEADA · Erleada · FIRMAGON · GEMTESA · GENERAL EMBOLICS · ILLUCCIX · JATENZO · JELMYTO · KEYTRUDA · LUPRON DEPOT · LYNPARZA · Lupron Depot · MYRBETRIQ · Myrbetriq · NOCDURNA · Natesto · Noctiva · Nubeqa · OES CYSTONEPHROFIBERSCOPE · ORGOVYX · OTREXUP · Olympus Laser Devices · Otrexup · POSLUMA · PROLARIS · PROVENGE · PYLARIFY · Prolaris · Prolia · REZUM · Rezum Generator · TISSEEL · TOVIAZ · VESICARE · XIAFLEX · XTANDI · XYOSTED · Xofigo · Xtandi · ZYTIGA · iTIND System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Urology physicians within 10 mi
82
Per 100K population
7.1
County median income
$101,763
Nearest hospital
REX HOSPITAL
2.6 mi
2.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Khera-McRackan is a mixed practice specialist, with above-average Medicare volume (top 4% in NC), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Khera-McRackan experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. Khera-McRackan performed 4,550 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Khera-McRackan receive payments from pharmaceutical companies?
Yes. Dr. Khera-McRackan received a total of $7,390 from 46 companies across 407 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Khera-McRackan's costs compare to other urology physicians in Raleigh?
Dr. Khera-McRackan's average Medicare payment per service is $22. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Khera-McRackan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Raleigh
Browse urology physicians in Raleigh ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in NC
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in NC
Which NC urology physicians receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Dendreon Pharmaceuticals LLC Payments to Doctors
See all physicians who received payments from Dendreon Pharmaceuticals LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology